JAK2阴性真性红细胞增多症
JAK2 Negative Polycythemia Vera.
作者信息
Geetha J P, Arathi C A, Shalini M, Srinivasa Murthy A G
机构信息
Department of Pathology, Sri Siddhartha Medical College, Tumkur, Karnataka, India.
出版信息
J Lab Physicians. 2010 Jul;2(2):114-6. doi: 10.4103/0974-2727.72215.
Abstract
Polycythemia vera (PV) is a stem cell disorder, characterized as a panhyperplastic, malignant, and neoplastic marrow disorder. Several reasons suggest that a mutation on the Janus kinase-2 gene (JAK2) is the most probable candidate gene involved in PV pathogenesis, as JAK2 is directly involved in intracellular signaling, following its exposure to cytokines, to which PV progenitor cells display hypersensitivity. A recurrent unique acquired clonal mutation in JAK2 was found in most patients with PV and other myeloproliferative diseases (MPDs). A female patient of age 50 years, presented with hemiplegia, diplopia, and had a consistent rise in hemoglobin and hematocrit. Serum Erythropoietin (Epo) was decreased. JAK2 mutation analysis was found to be negative. A diagnosis of polycythemia vera was made on the basis of the British Committee for Standards in Hematology (BCSH) guidelines.
摘要
真性红细胞增多症（PV）是一种干细胞疾病，其特征为全血细胞增生性、恶性和肿瘤性骨髓疾病。有几个原因表明，Janus激酶2基因（JAK2）突变是PV发病机制中最可能的候选基因，因为JAK2在暴露于细胞因子后直接参与细胞内信号传导，而PV祖细胞对这些细胞因子表现出超敏反应。在大多数PV患者和其他骨髓增殖性疾病（MPD）患者中发现了JAK2反复出现的独特获得性克隆突变。一名50岁女性患者出现偏瘫、复视，血红蛋白和血细胞比容持续升高。血清促红细胞生成素（Epo）降低。JAK2突变分析结果为阴性。根据英国血液学标准委员会（BCSH）指南做出了真性红细胞增多症的诊断。
相似文献
1
JAK2 Negative Polycythemia Vera.JAK2阴性真性红细胞增多症
J Lab Physicians. 2010 Jul;2(2):114-6. doi: 10.4103/0974-2727.72215.
2
The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.2001年世界卫生组织以及更新后的欧洲关于费城染色体阴性慢性骨髓增殖性疾病的诊断、分类及分期的临床和病理标准。
Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):307-40. doi: 10.1055/s-2006-942754.
3
Polycythemia vera: scientific advances and current practice.真性红细胞增多症：科学进展与当前实践
Semin Hematol. 2005 Oct;42(4):206-20. doi: 10.1053/j.seminhematol.2005.08.003.
4
The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.JAK2 V617F突变、自发性红细胞生成和巨核细胞生成、高敏血小板、活化白细胞以及内皮细胞在真性红细胞增多症和原发性血小板增多症血栓形成表现病因中的作用。
Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):381-98. doi: 10.1055/s-2006-942759.
5
Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis.真性红细胞增多症继发布加综合征患者血清促红细胞生成素水平升高：JAK2突变分析作用的临床意义
Eur J Haematol. 2006 Jul;77(1):57-60. doi: 10.1111/j.1600-0609.2006.00667.x.
6
A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.JAK2（V617F）中一种独特的激活突变是真性红细胞增多症的起源，并为骨髓增殖性疾病带来了新的分类。
Hematology Am Soc Hematol Educ Program. 2005:195-200. doi: 10.1182/asheducation-2005.1.195.
7
The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.血清促红细胞生成素水平及JAK2 V617F等位基因负荷在真性红细胞增多症诊断中的作用。
Br J Haematol. 2014 Nov;167(3):411-7. doi: 10.1111/bjh.13047. Epub 2014 Jul 18.
8
Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).慢性骨髓增殖性疾病（MPD）、原发性血小板增多症（ET）、真性红细胞增多症（PV）和慢性特发性骨髓纤维化（CIMF）的现行诊断标准。
Pathol Biol (Paris). 2007 Mar;55(2):92-104. doi: 10.1016/j.patbio.2006.06.002. Epub 2006 Aug 21.
9
Somatic JAK-2 V617F Mutational Analysis in Polycythemia Rubra Vera: a Tertiary Care Center Experience.真性红细胞增多症的体细胞JAK-2 V617F突变分析：一家三级医疗中心的经验
Asian Pac J Cancer Prev. 2016;17(3):1053-5. doi: 10.7314/apjcp.2016.17.3.1053.
10
Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.PRV-1 mRNA表达水平和JAK2V617F突变在真性红细胞增多症与继发性红细胞增多症鉴别诊断及干扰素或羟基脲治疗评估中的应用
Hematology. 2007 Dec;12(6):473-9. doi: 10.1080/10245330701384005.
引用本文的文献
1
Drug Repositioning via Graph Neural Networks: Identifying Novel JAK2 Inhibitors from FDA-Approved Drugs through Molecular Docking and Biological Validation.基于图神经网络的药物重定位：通过分子对接和生物学验证从 FDA 批准药物中鉴定新型 JAK2 抑制剂。
Molecules. 2024 Mar 19;29(6):1363. doi: 10.3390/molecules29061363.
2
A novel bone marrow-sparing treatment for primary erythrocytosis in a cat: Onion powder.一种用于治疗猫原发性红细胞增多症的新型骨髓保护疗法：洋葱粉。
J Vet Intern Med. 2021 Jul;35(4):1977-1980. doi: 10.1111/jvim.16194. Epub 2021 Jun 10.
3
Recurrent cerebral venous sinus thrombosis in a young man- A case report of -negative polycythemia vera.一名年轻男性复发性脑静脉窦血栓形成——真性红细胞增多症阴性的病例报告
J Family Med Prim Care. 2019 Oct 31;8(10):3422-3424. doi: 10.4103/jfmpc.jfmpc_628_19. eCollection 2019 Oct.
4
Erythrocytosis caused by giant chromophobe renal cell carcinoma: a case report indicating a 9-year misdiagnosis of polycythemia vera.巨大嫌色肾细胞癌所致红细胞增多症：一例提示真性红细胞增多症误诊9年的病例报告
Chin J Cancer. 2017 Sep 6;36(1):72. doi: 10.1186/s40880-017-0238-z.
本文引用的文献
1
The classification and diagnosis of erythrocytosis.红细胞增多症的分类与诊断
Int J Lab Hematol. 2008 Dec;30(6):447-59. doi: 10.1111/j.1751-553X.2008.01102.x. Epub 2008 Sep 23.
2
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.JAK2（V617F）阴性骨髓增殖性疾病患者中JAK2外显子12的体细胞突变
Blood. 2008 Feb 1;111(3):1686-9. doi: 10.1182/blood-2007-07-101576. Epub 2007 Nov 5.
3
Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.JAK2 V617F阴性真性红细胞增多症、红细胞增多症和原发性骨髓纤维化中的表型变异与新突变。
Exp Hematol. 2007 Nov;35(11):1641-6. doi: 10.1016/j.exphem.2007.08.010. Epub 2007 Oct 17.
4
Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis.真性红细胞增多症/红细胞增多症诊断与检查指南的修订
Br J Haematol. 2007 Sep;138(6):821-2. doi: 10.1111/j.1365-2141.2007.06741.x. Epub 2007 Aug 2.
5
Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests.JAK2 突变时代对“升高”血红蛋白的评估：基于基因检测的诊断算法
Mayo Clin Proc. 2007 May;82(5):599-604. doi: 10.4065/82.5.599.
6
Comparison of diagnostic criteria for polycythaemia vera.真性红细胞增多症诊断标准的比较。
Hematology. 2007 Apr;12(2):123-30. doi: 10.1080/10245330601111797.
7
Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.JAK2 V617F突变在慢性骨髓增殖性疾病中的致病作用。
J Chin Med Assoc. 2007 Mar;70(3):89-93. doi: 10.1016/S1726-4901(09)70337-5.
8
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.真性红细胞增多症和特发性红细胞增多症中的JAK2外显子12突变
N Engl J Med. 2007 Feb 1;356(5):459-68. doi: 10.1056/NEJMoa065202.
9
Polycythemia vera: scientific advances and current practice.真性红细胞增多症：科学进展与当前实践
Semin Hematol. 2005 Oct;42(4):206-20. doi: 10.1053/j.seminhematol.2005.08.003.
Zotero 插件